{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:26:36Z","timestamp":1762521996281},"reference-count":54,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interferon\u2010free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real\u2010world experience has been gathered in the last year and this paper presents data available in September 2016. Real\u2010world studies on the efficacy of the ledipasvir\/sofosbuvir (LDV\/SOF)\u00b1ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR rate in the 13858 patients included in this paper was 94%, and 92% in the 3506 patients with cirrhosis. In a number of recently published real\u2010world studies evaluating ombitasvir\/paritaprevir\/ritonavir (OBV\/PTV\/r)\u00b1dasabuvir (DSV)\u00b1RBV, the SVR rate was between 92% and 100%. The SVR rate of the 4260 patients included in the studies in this paper was 97% and the rate was the same in the 1647 patients with cirrhosis. Recently, data evaluating SOF\/simeprevir\u00b1RBV showed an SVR rate <jats:bold>&gt;<\/jats:bold>90%, while in combination with daclatasvir this rate reached approximately 95%. The safety data available for LDV\/SOF\u00b1RBV and OBV\/PTV\/r\u00b1DSV\u00b1RBV show that discontinuation due to adverse events was necessary in no more than 3% of patients and the frequency of serious adverse events was between 0 and 11%, in particular in real\u2010world studies. Because of the similar efficacy and safety, real\u2010world data support the use of either the LDV\/SOF\u00b1RBV or OBV\/PTV\/r\u00b1DSV\u00b1RBV regimen in patients with genotypes 1 or 4. There is still not enough real\u2010world data in patients with genotype 3 and other genotypes.<\/jats:p>","DOI":"10.1111\/liv.13293","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T04:15:37Z","timestamp":1484280937000},"page":"26-32","source":"Crossref","is-referenced-by-count":38,"title":["Hepatitis C: efficacy and safety in real life"],"prefix":"10.1111","volume":"37","author":[{"given":"Robert","family":"Flisiak","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Hepatology Medical University of Bia\u0142ystok  Bia\u0142ystok Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Pogorzelska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology Medical University of Bia\u0142ystok  Bia\u0142ystok Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Flisiak\u2010Jackiewicz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gastroenterology and Allergology Medical University of Bia\u0142ystok  Bia\u0142ystok Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03763.x"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2013.847089"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12294"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1057568"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0381-2"},{"issue":"2","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01554-3","article-title":"Real world effectiveness of ledipasvir\/sofosbuvir (LDV\/SOF) in treatment\u2010experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real\u2010world cohorts","volume":"64","author":"Curry M","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13696"},{"issue":"2","key":"e_1_2_14_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00200-2","article-title":"Evidence of impressive real world SVR from the Portuguese ledipasvir\/sofosbuvir and Sofosbuvir Universal Coverage Program to eradicate (eliminate) hepatitis C","volume":"64","author":"Rodrigues J","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)00196-3"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28625"},{"key":"e_1_2_14_16_1","article-title":"Real\u2010world outcomes of ledipasvir\/sofosbuvir in treatment\u2010naive patients with hepatitis C","volume":"22","author":"Younossi ZM","year":"2016","journal-title":"Am J Manag Care"},{"issue":"2","key":"e_1_2_14_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01581-6","article-title":"Ledipasvir\/sofosbuvir treatment for 8 weeks in treatment\u2010na\u012bve HCV genotype 1 infected patients under real life conditions: data from the German Hepatitis C\u2010Registry","volume":"64","author":"Buggisch P","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00188-4","article-title":"Effectiveness and safety of sofosbuvir\/ledipasvir treatment for monoinfected genotype 1 HCV patients in real\u2010life clinical practice: results from Spanish hepa\u2010C cohort","volume":"64","author":"Crespo J","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_19_1","first-page":"94","article-title":"Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir\/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study","volume":"62","author":"Terrault N","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_14_20_1","first-page":"80","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir\u00b1ribavirin in the real\u2010world HARVEST study","volume":"2","author":"Flisiak R","year":"2016","journal-title":"Clin Exp Hepatol"},{"issue":"2","key":"e_1_2_14_21_1","article-title":"Ledipasvir\/sofosbuvir for 8 weeks in non\u2010cirrhotic, treatment naive patients with genotype 1 hepatitis C infection: real life experience in a community setting","volume":"64","author":"Latt NL","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_22_1","article-title":"Safety and efficacy of new DAA regimens in kidney and liver transplant recipients with hepatitis C: interval results from the HCV\u2010target study","volume":"64","author":"Reddy KR","year":"2016","journal-title":"Hepatol"},{"issue":"2","key":"e_1_2_14_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00116-1","article-title":"Ledipasvir\/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection","volume":"64","author":"Colombo M","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00187-2","article-title":"Analysis of the real world effectiveness of direct acting antivirals treatments of hepatitis C in a large population","volume":"64","author":"McCombs J","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.10.013"},{"issue":"2","key":"e_1_2_14_26_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00127-6","article-title":"Prevalence and impact of baseline resistance\u2010associated variants on the efficacy of ledipasvir\/sofosbuvir or simeprevir\/sofosbuvir against gt1 HCV infection: HCV\u2010target interim analysis","volume":"64","author":"Wang G","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01603-2","article-title":"Treatment outcomes for hepatitis C genotype 1 infection with direct acting antivirals: data from the German Hepatitis C\u2010Registry","volume":"64","author":"Mauss S","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.021"},{"issue":"2","key":"e_1_2_14_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00189-6","article-title":"Effectiveness and safety of ombitasvir and paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from Spanish real world cohort","volume":"64","author":"Calleja J","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13790"},{"issue":"2","key":"e_1_2_14_31_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01641-X","article-title":"The real\u2010world Israeli experience treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir\/ritonavir\/ombitasvir, dasabuvir with or without ribavirin: a large multi\u2010center cohort","volume":"64","author":"Zuckerman E","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_32_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01460-4","article-title":"Ombitasvir\/paritaprevir\/ritonavir + dasabuvir + rybaviryn (3D + RBV) treatment of hepatitis C (HCV) genotype 1 (GT1) infected patients (pts) after failure to previous first generation protease\u2010inhibitor (PI) therapy. interim analysis","volume":"64","author":"Hunyady B","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_33_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01522-1","article-title":"Real world evaluation of Viekira Pak (ritonavir boosted paritaprevir, ombitasvir and dasabuvir\u00b1ribavirin) in HCV genotype 1 targeting advanced liver disease (The Revital Study)","volume":"64","author":"Lubel JS","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_34_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00191-4","article-title":"Analysis of the impact of HIV co\u2010infection on hepatitis c treatment effectiveness for patients using new direct\u2010acting antivirals","volume":"64","author":"McGinnis J","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01474-4","article-title":"Ledipasvir\/sofosbuvir+\/\u2212ribavirin in patients co\u2010infected with HCV and HIV: real\u2010world heterogeneous population from the Trio network","volume":"64","author":"Dieterich D","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01609-3","article-title":"Ledipasvir\/sofosbuvir+\/\u2212ribavirin in HCV post\u2010transplant patients: real\u2010world heterogeneous population from the Trio network","volume":"64","author":"Flamm S","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"e_1_2_14_37_1","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir\/dasabuvir +\/\u2212 ribavirin regimen for recurrent genotype 1 HCV infection after liver transplantation\u2014multicenter, real\u2010life, AMBER\u2010CEE study","volume":"100","author":"Tronina O","year":"2016","journal-title":"Transplantation"},{"issue":"2","key":"e_1_2_14_38_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01602-0","article-title":"Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir\u2010ledipasvir","volume":"64","author":"Rosenblatt R","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01453-7","article-title":"\u201cReal life\u201d data on DAAs use among HCV\u2010patients with moderate to severe chronic kidney disease not on hemodialysis","volume":"64","author":"Moreno A","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_40_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00986-7","article-title":"Renal dysfunction in liver transplant patients treated with sofosbuvir based\u2010regimen for HCV recurrence: results from a large French Prospective Multicentric ANRS CO23 CUPILT","volume":"64","author":"Anty R","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_41_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01588-9","article-title":"Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir are safety and efficacy for treating HCV GT1 and 4 infection in patients with severe renal impairment or end\u2010stage renal disease: a multicenter experience","volume":"64","author":"G\u00f3mez R","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.008"},{"issue":"2","key":"e_1_2_14_43_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00183-5","article-title":"Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"64","author":"Buonfiglioli F","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_44_1","article-title":"Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir\/daclatasvir with or without ribavirin\u20136 and 12 month outcomes compared to untreated patients","volume":"64","author":"Cheung MCM","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_45_1","first-page":"734","article-title":"Lack of evidence of an effect of direct acting antivirals on\u00a0the recurrence of hepatocellular carcinoma","volume":"66","author":"Pol S","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw387"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13769"},{"issue":"2","key":"e_1_2_14_48_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01532-4","article-title":"Real\u2010life outcomes of 8 weeks regimen of sofosbuvir and ledipasvir without ribavirin, in non\u2010cirrhotic treatment\u2010na\u00efve hepatitis C genotype 1 patients with less than 6 million IU\/ml viral load","volume":"64","author":"Qureshi K","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_49_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01556-7","article-title":"Effectiveness of ledipasvir\/sofosbuvir and ombitasvir\/paritaprevir\/ritonavir\/dasabuvir in treatment\u2010na\u00efve and\u2010experienced U.S. Veterans with genotype 1 hepatitis C infection","volume":"64","author":"Fuchs M","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_50_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)64004-7","article-title":"Safety and efficacy of directly acting antivirals in 2432 HCV patients with advanced fibrosis: an interim analysis of the Lombardia regional network for viral hepatitis","volume":"64","author":"Aghemo A","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_51_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01605-6","article-title":"Relapse and treatment\u2010ermergent ravs with DAA\u2010based regiments in hepatitis C virus infection (HCV) mono\u2010or\u2010human immunodeficiency virus (HIV)\u2010HCV Co\u2010infected patients\u2014a real concern in clinical practice? Results from the German hepatitis C cohort (GECCO)","volume":"64","author":"Christensen S","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_52_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01560-9","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir, with or without ribavirin, in patients with HCV genotype 4 infection\u2014real\u2010world experience from Qatar","volume":"64","author":"Derbala M","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_53_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01664-0","article-title":"Real\u2010world safety and effectiveness of ombitasvir\/paritaprevir with dasabuvir and\/or ribavirin in the German hepatitis C registry","volume":"64","author":"Hinrichsen H","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_54_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00631-0","article-title":"AVDLIB 2: news direct\u2010acting antiviral (DDA) in HCV patients with advanced liver disease. Final results of a the second multicenter prospective observational study in real life practice in France","volume":"64","author":"Ouzan D","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_14_55_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01487-2","article-title":"Dasabuvir and ombitasvir\/paritaprevir\/ritonavir with or without ribavirin in patients with HIV\u2010HCV coinfection: real life interim analysis of an Italian multicentre compassionate use program","volume":"64","author":"Teti S","year":"2016","journal-title":"J Hepatol"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T02:40:47Z","timestamp":1694659247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":54,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/liv.13293"],"URL":"https:\/\/doi.org\/10.1111\/liv.13293","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}